1 / 3

Drug Resistance

Drug Resistance. Mono-resistant TB – resistant to only one drug Poly-resistant TB – resistant to more than one drug but not the combination of isoniazid and rifampicin. Multidrug-resistant TB (MDR-TB ) TB caused by bacteria resistant to at least isoniazid and rifampicin.

susan
Download Presentation

Drug Resistance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Resistance Mono-resistant TB – resistant to only one drug Poly-resistant TB– resistant to more than one drug but not the combination of isoniazid and rifampicin. Multidrug-resistant TB (MDR-TB) • TB caused by bacteria resistant to at least isoniazid and rifampicin. Extensively drug-resistant TB (XDR-TB) • TB caused by bacteria resistant to isoniazid and rifampicin (i.e. MDR-TB) plus any fluoroquinolone and any second-line anti-TB injectable drugs (amikacin, kanamycin or capreomycin) There is an estimated 150 000 deaths per year from MDR-TB alone.

  2. Result from either primary infection with resistant bacteria or may develop secondarily in the course of treatment due to inadequate treatment regimens or poor compliance. • Risk factors include – • Previous treatment for TB especially if prolonged • Contact with a patient known to have drug resistant TB or live in an area with high drug-resistant TB prevalence • Immunocompromised (HIV in particular) • Poor compliance • Culture +ve after 2 months treatment • Can take up to 2 years to treat with drugs less potent, more toxic and more expensive. Higher mortality rate.

  3. Treatment is based on sensitivity testing with at least 3 drugs and an initial bactericidal injectable agent. • Fluoroquinolone should be used where possible. • XDR-TB Linezolid becomes mainstay treatment. Surgery is a limited option if disease localised.

More Related